Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$2.73 – $2.96
Volume2,377
Market cap$103M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
No ratio data was found for MOLN.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
No quarterly
income statement data was found for MOLN.
Recent news
Company coverage with links to the original publishers.
Molecular Partners announced preclinical data for MP0632, a logic-gated Switch-DARPin T cell engager targeting MSLN and EpCAM co-expressing tumors. The data demonstrates potent tumor cell killing comparable to clinical-stage benchmarks with improved safety profiles and no detectable impact on healthy tissues. The company plans to advance MP0632 into IND-enabling studies for solid tumors including ovarian, endometrial, lung, and pancreatic cancers.
Molecular Partners AG announced it will present data on its lead Radio-DARPin candidate MP0712, co-developed with Orano Med, at two major scientific conferences in November and December 2026. The presentations will include initial dose escalation data from a Phase 1/2a study in small cell lung cancer and other DLL3-expressing solid tumors, with efficacy data expected in the coming months.
Molecular Partners AG announced a strategic pivot to focus on radiopharmaceuticals, with its lead candidate MP0712 (DLL3-targeting Radio-DARPin) advancing in Phase 1/2a trials for small cell lung cancer. The company will reduce its workforce by up to 44% (~55 positions) to streamline operations, with changes implemented by Q2 2027. Initial safety data for MP0712 will be presented in December 2026, with efficacy data expected in 2027. The company has CHF 57.5 million in cash, expected to fund operations into late 2027.
Molecular Partners advanced its lead DLL3-targeting Radio-DARPin MP0712 to higher dose levels in Phase 1/2a trials with positive safety data, and selected CD70 as a new radiotherapy target for kidney cancer. The company reported a net loss of CHF 26.7 million in H1 2026 with cash reserves of CHF 67.9 million expected to fund operations into late 2027. Initial clinical data from MP0712 is anticipated in 2026 with efficacy data in 2027.
Molecular Partners AG announced that management will participate in a fireside chat at TD Cowen's 7th Annual Oncology Innovation Summit on May 27, 2026. The clinical-stage biotech company is developing DARPin therapeutics, a novel class of protein drugs, with lead candidate MP0712 progressing in Phase 1/2a trials with initial clinical data expected in 2026.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.